Sightline Wealth Advisors LLC Has $421,000 Stock Holdings in Global X Genomics & Biotechnology ETF $GNOM

Sightline Wealth Advisors LLC reduced its holdings in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 78.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,832 shares of the company’s stock after selling 38,796 shares during the period. Sightline Wealth Advisors LLC owned about 0.89% of Global X Genomics & Biotechnology ETF worth $421,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Halbert Hargrove Global Advisors LLC lifted its stake in Global X Genomics & Biotechnology ETF by 182.4% during the second quarter. Halbert Hargrove Global Advisors LLC now owns 13,685 shares of the company’s stock worth $115,000 after purchasing an additional 8,839 shares during the period. Atria Investments Inc raised its holdings in shares of Global X Genomics & Biotechnology ETF by 12.6% in the 2nd quarter. Atria Investments Inc now owns 18,520 shares of the company’s stock worth $156,000 after buying an additional 2,073 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Global X Genomics & Biotechnology ETF by 30.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after buying an additional 4,615 shares during the period. Creative Financial Designs Inc. ADV boosted its stake in Global X Genomics & Biotechnology ETF by 86.7% in the 2nd quarter. Creative Financial Designs Inc. ADV now owns 22,301 shares of the company’s stock valued at $188,000 after buying an additional 10,358 shares in the last quarter. Finally, Sei Investments Co. grew its position in Global X Genomics & Biotechnology ETF by 110.4% in the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after acquiring an additional 12,105 shares during the period. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Price Performance

Global X Genomics & Biotechnology ETF stock opened at $49.31 on Tuesday. The firm has a market capitalization of $53.75 million, a P/E ratio of -21.07 and a beta of 1.22. The stock has a fifty day moving average price of $46.77 and a two-hundred day moving average price of $41.58. Global X Genomics & Biotechnology ETF has a 52-week low of $27.20 and a 52-week high of $51.42.

Global X Genomics & Biotechnology ETF Announces Dividend

The company also recently declared a dividend, which was paid on Wednesday, January 7th. Investors of record on Tuesday, December 30th were issued a dividend of $0.5912 per share. This represents a yield of 259.0%. The ex-dividend date of this dividend was Tuesday, December 30th. Global X Genomics & Biotechnology ETF’s dividend payout ratio (DPR) is currently -26.50%.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.